Patrick Schwarz-Schütte
Chief Executive Officer at Black Horse Properties GmbH
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Daniel Lawton | M | - |
Promentis Pharmaceuticals, Inc.
 Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | - |
| Klaus Veitinger | M | 62 |
Promentis Pharmaceuticals, Inc.
Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | 16 years |
| Robert Mark Weisskoff | M | 61 |
Promentis Pharmaceuticals, Inc.
Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | - |
| Simone Bagel-Trah | M | 55 |
Heinrich-Heine-Universität Düsseldorf
| - |
| Sieghardt Rometsch | M | 85 |
Heinrich-Heine-Universität Düsseldorf
| - |
| Timothy J. Keane | M | 77 |
Promentis Pharmaceuticals, Inc.
Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | - |
| Chad E. Beyer | M | - |
Promentis Pharmaceuticals, Inc.
Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | 11 years |
| Michael P. Neary | M | - |
Promentis Pharmaceuticals, Inc.
Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | 14 years |
| Torsten Schreiber | M | - |
Black Horse Properties GmbH
 Black Horse Properties GmbH Real Estate DevelopmentFinance Black Horse Properties GmbH is a German company that buys and sells land, buildings, and apartments. The private company is based in Dusseldorf, Germany. The CEOs are Patrick Schwarz-Schütte, Torsten Schreiber, Michaela Steimel. The company was founded in 2014. | - |
| Hans-Peter Hartung | M | - |
Heinrich-Heine-Universität Düsseldorf
| 23 years |
| Michaela Steimel | F | 60 |
Black Horse Properties GmbH
Black Horse Properties GmbH Real Estate DevelopmentFinance Black Horse Properties GmbH is a German company that buys and sells land, buildings, and apartments. The private company is based in Dusseldorf, Germany. The CEOs are Patrick Schwarz-Schütte, Torsten Schreiber, Michaela Steimel. The company was founded in 2014. | 10 years |
| Peter Kalivas | M | - |
Promentis Pharmaceuticals, Inc.
Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | - |
| Dean Brostowin | M | - |
Promentis Pharmaceuticals, Inc.
Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Brian Tyler | M | 57 | - | |
| Thomas Duhnkrack | M | 70 |
University of Hamburg
| 4 years |
| Rolf Hollander | M | 73 |
University of Hamburg
| 8 years |
| Stephan Borchert | M | 54 | 3 years | |
| Andreas Franz Ludwig Heydemann | M | - |
University of Hamburg
| 5 years |
| Thomas R. Beck | M | 74 |
Promentis Pharmaceuticals, Inc.
Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | - |
| Jens J. Kruse | M | 65 |
University of Hamburg
| 5 years |
| Stephan Hinrichs | M | 64 |
University of Hamburg
| 7 years |
| Gert Michael Frank | M | - |
University of Hamburg
| 2 years |
| Christian Schröder | M | 69 |
University of Hamburg
| 4 years |
| Hartwig Kockläuner | M | 65 |
University of Hamburg
| 4 years |
| Florian Funck | M | 53 | 2 years | |
| Stacey Seltzer | F | 47 |
Promentis Pharmaceuticals, Inc.
Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | - |
| Petra Gerstenkorn | F | 70 |
University of Hamburg
| 7 years |
| Martin Fisher | M | 65 | 1 years | |
| Mohamed Idwan Ganie | M | 69 |
University of Hamburg
| 3 years |
| Marc E. Owen | M | 65 | 3 years | |
| Dietmar Kubis | M | 66 |
University of Hamburg
| 5 years |
| Dahai Yu | M | 62 |
University of Hamburg
| 5 years |
| Hanns-Ulrich Hasse | M | 65 |
University of Hamburg
| 5 years |
| Joachim Suesse | M | - |
University of Hamburg
| 4 years |
| Hock Wee Cheong | M | 66 |
University of Hamburg
| 4 years |
| Alain Vachon | M | 61 | 6 years | |
| Sheldon Garrison | M | - |
Promentis Pharmaceuticals, Inc.
Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | - |
| Gabriele Katharina Stall | F | 68 | 4 years | |
| Marc Binder | M | 53 | 7 years | |
| Klaus Ernst | M | 69 |
University of Hamburg
| 5 years |
| Ronan Brett | M | - | - | |
| Klaus Ernst Zimmermann | M | 67 |
University of Hamburg
| 3 years |
| Andreas Rieckhof | M | 65 |
University of Hamburg
| 7 years |
| Franz Christian Kalischer | M | 67 |
University of Hamburg
| 5 years |
| Stephan Gemkow | M | 64 | 2 years | |
| Andreas Kreimeyer | M | 69 |
University of Hamburg
| 5 years |
| Julius Michael Curtius | M | - | 25 years | |
| John Hammergren | M | 65 | - | |
| Paul C. Julian | M | 69 | 3 years | |
| Thomas Ebeling | M | 65 |
University of Hamburg
| 4 years |
| Christian Thormann | M | - |
University of Hamburg
| 6 years |
| Claus-Matthias Böge | M | 65 |
University of Hamburg
| 4 years |
| André Mangin | M | 70 |
University of Hamburg
| 6 years |
| Stefan Behn | M | 67 |
University of Hamburg
| 5 years |
| Itzchak Angel | M | - |
University of Hamburg
| 3 years |
| Ulli Gritzuhn | M | 62 |
University of Hamburg
| 6 years |
| Wilhelm Haarmann | M | 73 | 1 years | |
| Ulrich Wallin | M | 69 |
University of Hamburg
| 3 years |
| Sabine Göttgens | M | - | 1 years | |
| Hubertus Erlen | M | - | 11 years | |
| Andreas Preuß | M | 68 |
University of Hamburg
| 4 years |
| Dirk-Uwe Kerrmann | M | - | 10 years | |
| Markus Pinger | M | 61 | 2 years | |
| Karsten Heuchert | M | 70 |
University of Hamburg
| 4 years |
| Thomas H. Eckelmann | M | 73 |
University of Hamburg
| 1 years |
| Hanspeter Spek | M | 72 | 6 years | |
| Marion Helmes | M | 58 | 2 years | |
| Kai Kleeberg | M | 64 |
University of Hamburg
| 4 years |
| Jens Schreiber | M | - | - | |
| Wilken Freiherr von Hodenberg | M | 70 |
University of Hamburg
| 3 years |
| Pauline LindWall | F | 63 | 8 years | |
| Margret Suckale | F | 68 |
University of Hamburg
| 5 years |
| James Beer | M | 63 | 3 years | |
| Brigitte Falk | F | 61 | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Germany | 63 | 85.14% |
| United States | 11 | 14.86% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Patrick Schwarz-Schütte
- Personal Network
